DNA methylation of cancer genome

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 87, Issue 4, 2009, Pages 335-350

  Cheung, Hoi Hung ^a,b   Lee, Tin Lap ^a   Rennert, Owen M ^a   Chan, Wai Yee ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Cancer methylome; ChIP chip; ChIP seq; DNA methylation; Hypermethylation; Hypomethylation; mDIP; MeDIP; RLGS

Indexed keywords

CANCER GENETICS; CELL CYCLE REGULATION; DNA METHYLATION; DNA MICROARRAY; GENE IDENTIFICATION; GENETIC EPIGENESIS; GENOME; HUMAN; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EMBRYONIC DEVELOPMENT; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; GENOME; GENOMIC INSTABILITY; GENOMICS; HUMANS; MALE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PREGNANCY; REPETITIVE SEQUENCES, NUCLEIC ACID; RNA, NEOPLASM; RNA, UNTRANSLATED;

EID: 73249137306     PISSN: 1542975X     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrc.20163     Document Type: Review

References (189)

1. Akama TO, Okazaki Y, Ito M, et al. 1997. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res 57:3294-3299.
2. Alves G, Tatro A, Fanning T. 1996. Differential methylation of human LINE-1 retrotransposons in malignant cells. Gene 176:39-44.
3. Arnold CN, Goel A, Niedzwiecki D, et al. 2004. APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther 3:960-964.
4. Bachman KE, Herman JG, Corn PG, et al. 1999. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798-802.
5. Balch C, Yan P, Craft T, et al. 2005. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4:1505-1514.
6. Barski A, Zhao K. 2009. Genomic location analysis by ChIP-Seq. J Cell Biochem 107:11-18.
7. Bell AC, Felsenfeld G. 2000. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405:482-485.
8. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
9. Blanchard F, Tracy E, Smith J, et al. 2003. DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology 38:1516-1528.
10. Bourc'his D, Xu GL, Lin CS, et al. 2001. Dnmt3L and the establishment of maternal genomic imprints. Science 294:2536-2539.
11. Boyes J, Bird A. 1991. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64:1123-1134.
12. Cairns P. 2007. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 7:531-543.
13. Chan AW, Chan MW, Lee TL, et al. 2005. Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13:937-941.
14. Chan MW, Chan LW, Tang NL, et al. 2002. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464-470.
15. Cheah MS, Wallace CD, Hoffman RM. 1984. Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst 73:1057-1065.
16. Chedin F, Lieber MR, Hsieh CL. 2002. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci USA 99:16916-16921.
17. Chim CS, Wong AS, Kwong YL. 2003. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol 82:738-742.
18. Cho NY, Kim BH, Choi M, et al. 2007. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211:269-277.
19. Choi IS, Estecio MR, Nagano Y, et al. 2007. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol 20:802-810.
20. Cokus SJ, Feng S, Zhang X, et al. 2008. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452:215-219.
21. Costello JF, Fruhwald MC, Smiraglia DJ, et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138.
22. Dai Z, Zhu WG, Morrison CD, et al. 2003. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 12:791-801.
23. Daskalos A, Nikolaidis G, Xinarianos G, et al. 2009. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 124: 81-87.
24. Datta J, Kutay H, Nasser MW, et al. 2008. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68:5049-5058.
25. del Senno L, Barbieri R, Amelotti F, et al. 1986. Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine. Cancer Detect Prev 9:9-15.
26. Del Senno L, Maestri I, Piva R, et al. 1989. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol 142:146-149.
27. Detich N, Theberge J, Szyf M. 2002. Promoter-specific activation and demethylation by MBD2/demethylase. J Biol Chem 277:35791-35794.
28. Doctorow C. 2008. Big data: welcome to the petacentre. Nature 455:16-21.
29. Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al. 2004. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10:3972-3979.
30. Eckhardt F, Beck S, Gut IG, Berlin K. 2004. Future potential of the human epigenome project. Expert Rev Mol Diagn 4:609-618.
31. Estecio MR, Gharibyan V, Shen L, et al. 2007. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2:e399.
32. Esteve PO, Chin HG, Pradhan S. 2005. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci USA 102:1000-1005.
33. Fabre C, Grosjean J, Tailler M, et al. 2008. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 7: 2139-2145.
34. Fan M, Yan PS, Hartman-Frey C, et al. 2006. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966.
35. Fandy TE. 2009. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 16:2075-2085.
36. Fang JY, Zhu SS, Xiao SD, et al. 1996. Studies on the hypomethylation of cmyc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma. J Gastroenterol Hepatol 11:1079-1082.
37. Feinberg AP, Vogelstein B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92.
38. Felsberg J, Yan PS, Huang TH, et al. 2006. DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours. Neuropathol Appl Neurobiol 32:517-524.
39. Finocchiaro G, Mancuso FM, Cittaro D, Muller H. 2007. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME. Nucleic Acids Res 35:2343-2355.
40. Florl AR, Steinhoff C, Muller M, et al. 2004. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91:985-994.
41. Foltz G, Ryu GY, Yoon JG, et al. 2006. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 66:6665-6674.
42. Frommer M, McDonald LE, Millar DS, et al. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827-1831.
43. Fruhwald MC, O'Dorisio MS, Dai Z, et al. 2001. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 30:38-47.
44. Garcia-ManeroG, Daniel J, Smith TL, et al. 2002. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8:2217-2224.
45. Gaudet F, Hodgson JG, Eden A, et al. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492.
46. Goldston D. 2008. Big data: data wrangling. Nature 455:15.
47. Gonzalgo ML, Jones PA. 2002. Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods 27:128-133.
48. Griffiths EA, Gore SD. 2008. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45:23-30.
49. Gupta A, Godwin AK, Vanderveer L, et al. 2003. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63:664-673.
50. Hajkova P, Erhardt S, Lane N, et al. 2002. Epigenetic reprogramming in mouse primordial germ cells. Mech Dev 117:15-23.
51. Hanabata T, Tsukuda K, Toyooka S, et al. 2004. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep 12:177-180.
52. Hark AT, Schoenherr CJ, Katz DJ, et al. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405:486-489.
53. Hatada I, Hayashizaki Y, Hirotsune S, et al. 1991. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc Natl Acad Sci USA 88:9523-9527.
54. Henikoff S, Strahl BD, Warburton PE. 2008. Epigenomics: a roadmap to chromatin. Science 322:853.
55. Hesson L, Bieche I, Krex D, et al. 2004. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23:2408-2419.
56. Hoffman BG, Jones SJ. 2009. Genomewide identification of DNA-protein interactions using chromatin immunoprecipitation coupled with flow cell sequencing. J Endocrinol 201:1-13.
57. Honda T, Tamura G, Waki T, et al. 2004. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90:838-843.
58. Hong FZ, Wang B, Li HM, Liew CT. 2005. Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas. Zhonghua Bing Li Xue Za Zhi 34:257-261.
59. Huang TH, Perry MR, Laux DE. 1999. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8:459-470.
60. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. 2008. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112:2341-2351.
61. Jeronimo C, Usadel H, Henrique R, et al. 2001. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93:1747-1752.
62. Jiang C, Pugh BF. 2009. Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 10:161-172.
63. Johnson JM, Edwards S, Shoemaker D, Schadt EE. 2005. Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends Genet 21:93-102.
64. Jurgens B, Schmitz-Drager BJ, Schulz WA. 1996. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 56:5698-5703.
65. Kaneda M, Okano M, Hata K, et al. 2004. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429:900-903.
66. Kaneko Y, Shibuya M, Nakayama T, et al. 1985. Hypomethylation of cmyc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn J Cancer Res 76:1136-1140.
67. Kang GH, Lee HJ, Hwang KS, et al. 2003. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 163:1551-1556.
68. Kato K, Maesawa C, Itabashi T, et al. 2009. DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. Int J Oncol 35:467-476.
69. Kempkensteffen C, Christoph F, Weikert S, et al. 2006. Epigenetic silencing of the putative tumor suppressor gene testisin in testicular germ cell tumors. J Cancer Res Clin Oncol 132:765-770.
70. Keshet I, Schlesinger Y, Farkash S, et al. 2006. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 38:149-153.
71. Khulan B, Thompson RF, Ye K, et al. 2006. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 16:1046-1055.
72. Kim DH, Nelson HH, Wiencke JK, et al. 2001. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20:1765-1770.
73. Kim DH, Kim JS, Park JH, et al. 2003. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 63:6206-6211.
74. Kim KH, Choi JS, Kim IJ, et al. 2006. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J Gastroenterol 12:5651-5657.
75. Kimura H, Shiota K. 2003. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 278:4806-4812.
76. Koike K, Matsuyama T, Ebisuzaki T. 2008. Epigenetics: application of virtual image restriction landmark genomic scanning (Vi-RLGS). FEBS J 275:1608-1616.
77. Konishi N, Tao M, Nakamura M, et al. 1996. Genomic alterations in human prostate carcinoma cell lines by two-dimensional gel analysis. Cell Mol Biol (Noisy-le-grand) 42:1129-1135.
78. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
79. Kuromitsu J, Kataoka H, Yamashita H, et al. 1995. Reproducible alterations of DNA methylation at a specific population of CpG islands during blast formation of peripheral blood lymphocytes. DNA Res 2:263-267.
80. Lee EJ, Lee BB, Kim JW, et al. 2006a. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 42:972-980.
81. Lee TL, Leung WK, Chan MW, et al. 2002. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8:1761-1766.
82. Lee TL, Yeh J, Van Waes C, Chen Z. 2006b. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5:8-19.
83. Lee TL. 2008. Big data: open-source format needed to aid wiki collaboration. Nature 455:461.
84. Lei H, Oh SP, Okano M, et al. 1996. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122:3195-3205.
85. Leung WK, Yu J, Ng EK, et al. 2001. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 91:2294-2301.
86. E, Bestor TH, Jaenisch R. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69:915-926.
87. LC, Shiina H, Deguchi M, et al. 2004. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 321:455-461.
88. Licchesi JD, Herman JG. 2009. Methylation-specific PCR. Methods Mol Biol 507:305-323.
89. Lim JH, Kim SP, Gabrielson E, et al. 2005. Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation. Int J Cancer 116:200-206.
90. Lind GE, Skotheim RI, Lothe RA. 2007. The epigenome of testicular germ cell tumors. APMIS 115:1147-1160.
91. Lister R, Ecker JR. 2009. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res 19:959-966.
92. Lister R, O'Malley RC, Tonti-Filippini J, et al. 2008. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133:523-536.
93. Lujambio A, Ropero S, Ballestar E, et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67:1424-1429.
94. Lujambio A, Calin GA, Villanueva A, et al. 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556-13561.
95. Maruyama R, Sugio K, Yoshino I, et al. 2004. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100:1472-1477.
96. Mayer W, Niveleau A, Walter J, et al. 2000. Demethylation of the zygotic paternal genome. Nature 403:501-502.
97. Meissner A, Mikkelsen TS, Gu H, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766-770.
98. Milicic A, Harrison LA, Goodlad RA, et al. 2008. Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res 68:7760-7768.
99. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. 2007. Cancer genetics of epigenetic genes. Hum Mol Genet 16 Spec No 1:R28-R49.
100. Mohn F, Weber M, Schubeler D, Roloff TC. 2009. Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol 507:55-64.
101. Morey SR, Smiraglia DJ, James SR, et al. 2006. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res 66:11659-11667.
102. Morozova O, Marra MA. 2008. Applications of next-generation sequencing technologies in functional genomics. Genomics 92:255-264.
103. Motiwala T, Ghoshal K, Das A, et al. 2003. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 22:6319-6331. Muromoto R, Sugiyama K, Takachi A, et al. 2004. Physical and functional interactions between Daxx and DNA methyltransferase 1-associated protein, DMAP1. J Immunol 172:2985-2993.
104. Nagai H, Kim YS, Yasuda T, et al. 1999. A novel sperm-specific hypomethylation sequence is a demethylation hotspot in human hepatocellular carcinomas. Gene 237:15-20.
105. Nakata S, Sugio K, Uramoto H, et al. 2006. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106:2190-2199.
106. Nambu S, Inoue K, Saski H. 1987. Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn J Cancer Res 78:695-704.
107. Nan HM, Song YJ, Yun HY, et al. 2005. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol 11:3834-3841.
108. Nan X, Meehan RR, Bird A. 1993. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21: 4886-4892.
109. Neff T, Armstrong SA. 2009. Chromatin maps, histone modifications and leukemia. Leukemia 23:1243-1251.
110. Ng HH, Zhang Y, Hendrich B, et al. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23:58-61.
111. Nosho K, Yamamoto H, Takahashi T, et al. 2007. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28:1364-1370.
112. Oda M, Greally JM. 2009. The HELP assay. Methods Mol Biol 507:77-87.
113. Ogino S, Kawasaki T, Kirkner GJ, et al. 2007. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 56:1564-1571.
114. Ogino S, Kawasaki T, Nosho K, et al. 2008. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 122:2767-2773.
115. Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257.
116. Okazaki Y, Okuizumi H, Sasaki N, et al. 1995. An expanded system of restriction landmark genomic scanning (RLGS Ver. 1.8). Electrophoresis 16:197-202.
117. Ongenaert M, Van Neste L, De Meyer T, et al. 2008. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36:D842-D846.
118. Ordway JM, Budiman MA, Korshunova Y, et al. 2007. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One 2:e1314.
119. Oswald J, Engemann S, Lane N, et al. 2000. Active demethylation of the paternal genome in the mouse zygote. Curr Biol 10:475-478.
120. Oue N, Oshimo Y, Nakayama H, et al. 2003. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 94:901-905.
121. Paredes J, Albergaria A, Oliveira JT, et al. 2005. P-cadherin over-expression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11:5869-5877.
122. Pattamadilok J, Huapai N, Rattanatanyong P, et al. 2008. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18:711-717.
123. Paz MF, Wei S, Cigudosa JC, et al. 2003. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 12:2209-2219.
124. Pettersson E, Lundeberg J, Ahmadian A. 2009. Generations of sequencing technologies. Genomics 93:105-111.
125. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. 2000. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 97:5237-5242.
126. Reilly JG, Thomas CA, Jr, Sen A. 1982. DNA methylation in mouse cells in culture as measured by restriction enzymes. Biochim Biophys Acta 697:53-59.
127. Ren B, Dynlacht BD. 2004. Use of chromatin immunoprecipitation assays in genome-wide location analysis of mammalian transcription factors. Methods Enzymol 376:304-315.
128. Robertson KD, Ait-Si-Ali S, Yokochi T, et al. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338-342.
129. Robertson KD. 2005. DNA methylation and human disease. Nat Rev Genet 6:597-610.
130. Rodriguez BA, Huang TH. 2005. Tilling the chromatin landscape: emerging methods for the discovery and profiling of protein-DNA interactions. Biochem Cell Biol 83:525-534.
131. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. 2004. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104:2492-2498.
132. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. 2005a. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24:7213-7223.
133. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. 2005b. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 23:7043-7049.
134. Rountree MR, Bachman KE, Baylin SB. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25:269-277.
135. Saito Y, Liang G, Egger G, et al. 2006. Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443.
136. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
137. Sanger F, Nicklen S, Coulson AR. 1992. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 24:104-108.
138. Sarbia M, Geddert H, Klump B, et al. 2004. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 111:224-228.
139. Sato S, Yoshimizu T, Sato E, Matsui Y. 2003. Erasure of methylation imprinting of Igf2r during mouse primordial germ-cell development. Mol Reprod Dev 65:41-50.
140. Saxonov S, Berg P, Brutlag DL. 2006. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103:1412-1417.
141. Schneider-Stock R, Ocker M. 2007. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 10:557-561.
142. Schumacher A, Kapranov P, Kaminsky Z, et al. 2006. Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res 34:528-542.
143. Sharrard RM, Royds JA, Rogers S, Shorthouse AJ. 1992. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 65:667-672.
144. Shendure J. 2008. The beginning of the end for microarrays? Nat Methods 5:585-587.
145. Shiozawa E, Takimoto M, Makino R, et al. 2006. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res 30:859-867.
146. Shivakumar L, Minna J, Sakamaki T, et al. 2002. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22:4309-4318.
147. Shuangshoti S, Hourpai N, Pumsuk U, Mutirangura A. 2007. Line-1 hypomethylation in multistage carcinogenesis of the uterine cervix. Asian Pac J Cancer Prev 8:307-309.
148. Siu LL, Chan JK, Wong KF, Kwong YL. 2002. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 160:59-66.
149. Smallwood A, Esteve PO, Pradhan S, Carey M. 2007. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 21:1169-1178.
150. Smiraglia DJ, Plass C. 2002. The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene 21:5414-5426.
151. Smiraglia DJ, Smith LT, Lang JC, et al. 2003. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40:25-33.
152. Smiraglia DJ, Kazhiyur-Mannar R, Oakes CC, et al. 2007. Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics 8:446.
153. Smith JF, Mahmood S, Song F, et al. 2007. Identification of DNA methylation in 30 genomic regions that are associated with upregulation of gene expression in colorectal cancer. Epigenetics 2:161-172.
154. Solomon MJ, Larsen PL, Varshavsky A. 1988. Mapping protein-DNA interactions in vivo with formaldehyde: evidence that histone H4 is retained on a highly transcribed gene. Cell 53:937-947.
155. Song F, Smith JF, Kimura MT, et al. 2005. Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci USA 102:3336-3341.
156. Sorensen AL, Collas P. 2009. Immunoprecipitation of methylated DNA. Methods Mol Biol 567:249-262.
157. Suzuki M, Shigematsu H, Iizasa T, et al. 2006. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106:2200-2207.
158. Tate PH, Bird AP. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3:226-231.
159. Teodoridis JM, Hall J, Marsh S, et al. 2005. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967.
160. Thu KL, Vucic EA, Kennett JY, et al. 2009. Methylated DNA immunoprecipitation. J Vis Exp 23:935.
161. To KF, Leung WK, Lee TL, et al. 2002. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 102:623-628.
162. Tsukamoto N, Morita K, Karasawa M, Omine M. 1992. Methylation status of c-myc oncogene in leukemic cells: hypomethylation in acute leukemia derived from myelodysplastic syndromes. Exp Hematol 20:1061-1064.
163. Vire E, Brenner C, Deplus R, et al. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874.
164. Vladimirova V, Mikeska T, Waha A, et al. 2009. Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia 11:700-711.
165. Waha A, Koch A, Hartmann W, et al. 2007. SGNE1/7B2 is epigenetically altered and transcriptionally down-regulated in human medulloblastomas. Oncogene 26:5662-5668.
166. Waldrop M. 2008. Big data: wikiomics. Nature 455:22-25.
167. Wang JC. 2005. Finding primary targets of transcriptional regulators. Cell Cycle 4:356-358.
168. Wang Q, Williamson M, Bott S, et al. 2007. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26:6560-6565.
169. Wang SS, Smiraglia DJ, Wu YZ, et al. 2008. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 68:2489-2497.
170. Weber B, Stresemann C, Brueckner B, Lyko F. 2007a. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6:1001-1005.
171. Weber M, Davies JJ, Wittig D, et al. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37:853-862.
172. Weber M, Hellmann I, Stadler MB, et al. 2007b. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457-466.
173. Widschwendter M, Jiang G, Woods C, et al. 2004a. DNA hypomethylation and ovarian cancer biology. Cancer Res 64:4472-4480.
174. Widschwendter M, Siegmund KD, Muller HM, et al. 2004b. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807-3813.
175. Willingham AT, Gingeras TR. 2006. TUF love for "junk" DNA. Cell 125: 1215-1220.
176. Woodson K, Hayes R, Wideroff L, et al. 2003. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 55:199-205.
177. Wu J, Smith LT, Plass C, Huang TH. 2006. ChIP-chip comes of age for genome-wide functional analysis. Cancer Res 66:6899-6902.
178. Xiong Z, Laird PW. 1997. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25:2532-2534.
179. Yamagata Y, Maekawa R, Asada H, et al. 2009. Aberrant DNA methylation status in human uterine leiomyoma. Mol Hum Reprod 15:259-267.
180. Yan PS, Perry MR, Laux DE, et al. 2000. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 6:1432-1438.
181. Yan PS, Venkataramu C, Ibrahim A, et al. 2006. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626-6636.
182. Yanagawa N, Tamura G, Honda T, et al. 2004. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 10:2447-2451.
183. Yu J, Zhang H, Gu J, et al. 2004. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4:65.
184. Yu MY, Tong JH, Chan PK, et al. 2003. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105:204-209.
185. Zhang Q, Wang HY, Marzec M, et al. 2005a. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 102:6948-6953.
186. Zhang YJ, Chen Y, Ahsan H, et al. 2005b. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett 221:135-143.
187. Zhao W, Liu H, Liu W, et al. 2006. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 28:1081-1088.
188. Zhou D, Qiao W, Yang L, Lu Z. 2006. Bisulfite-modified target DNA array for aberrant methylation analysis. Anal Biochem 351:26-35.
189. Zochbauer-Muller S, Fong KM, Virmani AK, et al. 2001. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249-255.